US2018355015A1PendingUtilityA1

Methods and materials for generating t cells

63
Assignee: MAYO FOUND MEDICAL EDUCATION & RESPriority: Feb 19, 2009Filed: Jun 20, 2018Published: Dec 13, 2018
Est. expiryFeb 19, 2029(~2.6 yrs left)· nominal 20-yr term from priority
Inventors:Keith L. Knutson
A61K 2039/6031C12N 2501/998A61K 2039/64C07K 7/08C07K 2319/33C07K 2319/50A61P 37/04C07K 5/101A61K 39/385C07K 2319/01C07K 14/70539A61K 2039/5158C12N 5/0636A61K 40/4205A61K 40/4202A61K 40/24A61K 40/19A61K 40/11A61K 2239/38A61K 2239/31
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The document provides to methods and materials for generating T cells (e.g., antigen-specific CD4+ T cells). For example, methods and materials for using nested MHC class II epitopes as vaccines to generate activated CD4+ T cells in vivo or as reagents to generate activated CD4+ T cells ex vivo are provided.

Claims

exact text as granted — not AI-modified
1 - 16 . (canceled) 
     
     
         17 . A method for activating T cells in a mammal, said method comprising administering a composition comprising an acetylated polypeptide to said mammal, wherein said polypeptide comprises LRMK (SEQ ID NO:44) followed by aminovaleric acid followed by QCRPWRKNACCSTNT (SEQ ID NO:33) followed by RARR (SEQ ID NO:4) followed by FYPSYHSTPQRP (SEQ ID NO:2), wherein said polypeptide is between 20 and 80 amino acids in length.

Join the waitlist — get patent alerts

Track US2018355015A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.